Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
As
Novo Nordisk
prepares to phase out some forms of its
human premix insulin
brand Mixtard-a move seen overlapping with its planned launch of
weight-loss drug Wegovy
in India-other top insulin makers are rushing to ramp up production capacity to bridge the potential demand-supply gap the move is expected to create, said top company executives.
The Danish pharma major, the maker of semaglutide blockbusters Ozempic and Wegovy, is planning to retire a range of insulin formulations available in easy-to-use disposable pen and cartridge forms by the end of this year. This would include human insulin in penfill and flexpen, including Mixtard 30 Penfill and Flexpen, Actrapid Penfill and Flexpen, Insulatard Penfill and Flexpen, and Mixtard 50 Penfill over the next six months. It will also phase out insulin brand Levemir in FlexPen and Xultophy FlexTouch (Insulin + GLP1).
The company recently informed
Abbott India
about this planned phase-out, according to a document accessed by ET. Abbott is the marketing partner for Novo's insulin.
Confirming the development, a Novo Nordisk spokesperson said, "In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio, as this will create space needed in our global manufacturing network. Hence, in this process, we are phasing out the penfill."
However, the company said it is not discontinuing Mixtard in India and "it will continue to be available in vials". The company did not provide any details on specific brands.
"Along with it, other forms of insulins, including human insulins from Novo Nordisk, will continue to be available in vials and devices for patients across India," the spokesperson said. "With the decision, we strive not to leave any patients without alternative treatment options, either from Novo Nordisk or other companies. It is important to us that the transition to other devices or treatment options is as smooth as possible for patients."
The phasing out of the penfill Mixtard creates an opportunity for other human premix insulin makers such as
Lupin
, Eris, Eli Lilly,
Wockhardt
and
Cadila
, said industry insiders.
Amit Bakshi, MD,
Eris Lifesciences
, which is ramping up capacity to produce penfill insulin said, "Our strategy is to make sure how we are available through and through and how we can ramp up manufacturing."
However, according to him the transition phase may be a "small level of emergency", as a lot of hoarding has been happening in the last couple of months after the news has been out, with several large stockists and patients increasing their stock.
"We may not be able to take on all of the demand immediately but are planning to take 60-70% of it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
an hour ago
- The Print
Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market
Insulin is a hormone that helps move glucose (sugar) from the bloodstream into cells to stop it from building up in the bloodstream. Patients with type 1 diabetes or advanced type 2 diabetes need to administer insulin, typically multiple times a day, in order to keep their blood sugar in a healthy range. Now, with a number of Indian drugmakers foraying into the insulin market in the country once dominated by multinational drugmakers—Big Pharma, its cost is expected to dip further. New Delhi: Insulin, a lifeline for nearly all patients with type 1 diabetes and nearly 10 percent of those with type 2 diabetes, is available in India at an average cost of Rs 133 per vial—among the cheapest in the world. With the country seeing a near explosion of diabetes, the size of India's insulin market stood at an estimated Rs 4,404 crore in April this year, according to Pharmatrac, a market research company that tracks the Indian drug market. Its April report, the latest, which ThePrint has seen, said, 'Indian players are making a steady entry in the Insulins market that was once dominated by MNCs'. Four Indian companies have launched various insulin brands in India over the last two years in the segment where multinationals such as Novo Nordisk, Eli Lilly and Company and Sanofi have ruled the roost, according to Pharmatrac statistics. It added that with innovator companies like Eli Lilly and Novo Nordisk increasingly focusing on the anti-obesity segment (Mounjaro, Ozempic and Wegovy), it opens 'doors of opportunity for the Indian players' to expand their footprint. According to data from the Pharmatrac report, of over 90 insulin brands available in the Indian market, 14 have a collective market share of more than 80 percent. Of these, 11 are owned by either Novo Nordisk, which has a tie-up with Abbott for marketing them in India, or Sanofi, while one brand, Huminsulin by US-based pharma giant Eli Lilly, was sold to Indian drugmaker Lupin last year. The two best-selling insulin brands in the country include Mixtard and Ryzodeg, both by Danish drugmaker Novo Nordisk. Mixtard alone has a market of over Rs 800 crore in India. The only Indian company, which has two brands among the top-selling 14 insulin brands, is Ahmedabad-based Eris Lifesciences. Indian companies that have entered the segment since 2023 include USV, Anthem Biopharma, Cadila and Mankind. Additionally, Cipla, following a strategic tie-up with Eli Lilly, launched its insulin drug, Lyumjev, in India in October 2023. Pharmatrac statistics also showed that Indian companies, which include Eris Lifesciences, Cipla and Mankind, apart from Lupin, sold insulin worth Rs 1,088 crore between April 2024 and April 2025—24.7 percent of the total insulin market. However, as of now, a large number of diabetics in need of insulin still cannot access or afford the new generation versions that are more convenient to use, and most new brands being launched in India have yet to address this issue. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Further price crashes expected In 2023, the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation estimated that nearly 101 million people in India had diabetes. It is suggested that while the majority with the condition have type 2 diabetes, the number of those with type 1 is also estimated to be around 9 lakh, and this includes a large number of those under 18 years of age. Type 1 diabetes, say experts, is characterised by complete loss of the insulin-producing beta cells due to an autoimmune disease or idiopathic (unknown) reasons. Type 2 diabetes, also called diabetes mellitus, on the other hand, is mainly triggered by insulin resistance or the body's inability to respond to insulin, often combined with relatively reduced insulin secretion and is linked with lifestyle issues such as poor dietary habits and lack of physical activity. Nearly 10 percent of patients with type 2 diabetes, mainly those in the advanced or severe stage of the condition, require insulin, but for all patients with type 1 diabetes, insulin is mandatory, mostly 3-4 times a day Type 1 diabetes is growing at a rate of 6.7 percent annually in India, compared to 4.4 percent for type 2 diabetes, the latest Pharmatrac report noted. Diabetologist and researcher Dr V. Mohan underlined that the exact reason why the number of people with type 1 diabetes is growing may not be properly understood, but it could also be due to better awareness about the condition and quicker diagnosis. 'Earlier, many with type 1 diabetes used to die within years of disease onset as they did not get insulin on time, but now they are living longer, and those with type 2 diabetes, after living with the condition for years, typically need insulin,' he said. This is why, the clinician-researcher said, the insulin segment is growing rapidly in the country. Adding, 'More competition is always good because that will help to keep up the quality of the product and also bring down the price of the insulin.' Industry insiders said the trend of Indian firms entering the segment was mainly prompted by expiration of patents on key insulin analogues and rapid global adoption of GLP-1 analogues like semaglutide and tirzepatide, used for diabetes and obesity management 'With diabetes now recognised as a national health priority, domestic companies are investing in biosimilar innovation, scaling production capabilities, and forming strategic collaborations to secure insulin supply for the domestic market,' said Saransh Chaudhary, president (global critical care) of research-driven pharma company Venus Remedies. Innovative therapy, devices for diabetics Till the 70s the insulin used by those in need was derived from animals like pigs and cows, while the 80s saw the advent of human insulin, a type of synthetic insulin made in a laboratory that mimics the insulin our body makes. Over the last 15-20 years, insulin analogues, which are more convenient and quicker to act, have been in use in developed countries. This type of medicine is made in the same way as human insulin but is genetically altered to change the way it acts in the body. More expensive than human insulin, insulin analogues have a different chemical structure and are designed to act more rapidly, within 5-10 minutes of administration and for a longer time of up to 40 hours, ensuring ease in diabetes care. These often come in specifically designed devices such as pre-filled pens that are simply administered through a click, instead of most human insulins in vials that have to be administered as an injection. However, as these formulations are not part of the National List of Essential Medicines (NLEM) and are costlier—typically costing Rs 10,000-15,000 per month—most Indian diabetics in need of insulin therapy cannot afford them. As of now, only some basic formulations of insulin are on the NLEM, whose upper price ceilings are fixed by the government. Once protected by patent, as some of them are now off-patent, their biosimilar versions—just like generics in case of small molecule drugs—have now hit the Indian market, and it could change the affordability issue, underlined Dr Manisha Arora, director, internal Medicine at the CK Birla Hospital. 'The entry of multiple pharmaceutical companies into this space reflects the segment's growth potential and the opportunity to enhance treatment outcomes through competitive pricing and technological advancements,' she said. Increased competition could spur further innovation, improve patient-centric delivery systems, and contribute to a more sustainable and equitable diabetes care ecosystem, Arora added. (Edited by Sanya Mathur) Also Read: ICMR-led consortium seeks health tax on fat, sugar & salt-rich foods to cut adolescent obesity burden
Hans India
an hour ago
- Hans India
TN to launch ‘Social Labs', ‘Learn-a-Lot' to empower over 60,000 hostel students
Chennai: In a significant step to enhance educational and personal development among marginalised communities, the Tamil Nadu government's Adi Dravidar and Tribal Welfare Department is set to roll out two major initiatives -- Social Labs and Learn-a-Lot -- targeting more than 60,000 students staying in government-run hostels across the state. The initiatives are specially designed for first-generation learners from economically disadvantaged backgrounds, most of whose families earn less than Rs 2.5 lakh per annum. While basic academic needs are met in these hostels, officials say there remains a gap in providing structured support for skill development, career readiness, and life skills. 'According to the Heckman Curve, the highest rate of return on investment in human capital comes from early interventions. These two programmes aim to bridge critical gaps in students' academic and personal growth,' a senior department official said. The Social Labs programme will cater to students in 174 college hostels, covering around 12,910 students. Its primary objective is to build employability, boost self-confidence, and foster a mentorship ecosystem. Training modules will include spoken English, personality development, MS Office, Tally, arts, and sports. 'The goal is to ensure these students are not just college-ready but job-ready,' the official added. On the other hand, the Learn-a-Lot programme is designed for school students residing in 997 hostels, benefitting nearly 44,500 children. This initiative adopts a holistic approach, combining curriculum-based academic support with co-scholastic development and life skill education. Students will receive training in STEM subjects, digital literacy, fine arts, sports, value education, and career guidance. Recognising the differing needs of school and college students, the department has tailored each programme accordingly. 'The difference in both initiatives stems from the stage of life the students are in. Learn-a-Lot focuses on foundational skills, while Social Labs gears students toward professional and interpersonal growth,' the official explained. Both programmes will be implemented through a zone-wise strategy and delivered in flexible formats -- online, offline, or blended -- depending on the infrastructure available in each location. Officials believe these initiatives will empower students to unlock their full potential and break the cycle of poverty through education and skill development.
NDTV
20 hours ago
- NDTV
"Blown Away": Former Danish Ambassador On Adani Group's Khavda Renewable Energy Park
Copenhagen/New Delhi: Freddy Svane, the former Danish Ambassador to India, on Sunday said he was "blown away" by the magnitude of the Adani Group's mega renewable energy (RE) park in Gujarat's Khavda. Speaking to IANS, Svane, a well-travelled and highly experienced diplomat, visited Khavda RE park - the world's largest - in November last year, along with ambassadors from the European Union (EU), Belgium, and Germany. "I was so blown away by the magnitude and the kind of strategy aligned behind it. It was an eye opener, and shows that the green transition, green strategic cooperation, whatever we call it, is so important," he said. Svane further stated that such green energy projects are not only good for bilateral relations but also a must for humanity, as "we need to have a better and more sustainable world". "Our next generations will be suffering if we don't solve this climate crisis," the former Ambassador told IANS. During the ambassadors' visit, Gautam Adani, Chairman of the Adani Group, had said it was a privilege to host them. Gautam Adani said the discussions with the envoys focused on strengthening global partnerships to drive India's energy transition and accelerate the hydrogen ecosystem. "It was a privilege to host the ambassadors from the EU, Belgium, Denmark and Germany at our office. I deeply appreciate their visit to the world's largest renewable energy park in Khavda, Gujarat, and India's largest port, logistics and industrial hub in Mundra," the Adani Group Chairman had posted on social media platform X. The discussions were "truly insightful, focusing on strengthening global partnerships to drive India's energy transition and accelerate the hydrogen ecosystem," said the billionaire industrialist, adding: "At Adani, we continue to drive forward with our ambitious renewable energy initiatives while ensuring a balanced energy mix that supports a sustainable future for all of India". Svane further said he was so pleased when Prime Minister Narendra Modi came to Denmark, and "we could really take the green strategic partnership forward, which is so important". "I do hope that it will also inspire others because what can be done bilaterally is not enough. It calls for a kind of global action, like the fight against terror," Svane told IANS. PM Modi paid an official visit to Denmark on May 3-4, 2022 and had bilateral talks with his Danish counterpart, Mette Frederiksen. During the talks, the two Prime Ministers reviewed the progress of India-Denmark Green Strategic Partnership and exchanged views on regional and global issues of mutual interest.
